Attention Deficit Hyperactivity Disorder Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period

28/mag/2018 14:38:22 PBIGP Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Attention Deficit Hyperactivity Disorder Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period

 

Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) market: Attention deficit hyperactivity disorder also known as hyperkinetic disorder/ neuropsychiatric disorder is one of the most common brain disorder characterized by symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children as compared to older population. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to genetic factors and environmental factors.

 

It results in improper functioning of the nervous system that led to inattentiveness and hyperactivity/impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The treatment includes different modalities such as medication, psychotherapy, and education/training.

 

The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) market is growing due to changing in lifestyle and systems impacting the quality of the births. Compromised children’s diet with preservatives, increased cases of ADHD in children, increasing awareness among patients and physicians about ADHD treatment are expected to further grow the treatment market for ADHD. However, the presence of comorbid conditions in children leads to underdiagnoses of ADHD treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of the market.

 

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-4H8Z4LpNMLEuOnnx

 

The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market can be categorized as-

1.      Medication type

·         Stimulants

o    Amphetamines

o    Methylphenidate

o    Dextroamphetamine

o    Dexmethylphenidate

·         Non-Stimulants

o    Atomoxetine

o    Bupropion

o    Guanfacine

2.     Age group

·         Pediatric

·         Adolescent

·         Adults

3.     End-users

Pharmacies such hospital, retail, online pharmacies and specialty clinics.

 

Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-c654SbFYO64MsOhu

 

And lastly on the basis of geographical regions, the global ADHD market has five major regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds the largest share in global ADHD treatment market due to rising prevalence of ADHD, increase in healthcare expenditure, ongoing clinical trials, and an early approval of drugs in the U.S., favorable insurance policies and technological advancement for the treatment will fuel the ADHD treatment market. Europe accounts for the significant share due to increase in the population, rising prevalence of ADHD patients, and increased R & D for the innovation of new products. Asia-Pacific holds a dominant share in market owing to developing healthcare infrastructure, government initiatives, etc. 

 

Ask Analyst for Full Information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-14mlyhjMGhVjZqa3

 

Some of the key players in the global attention deficit hyperactivity disorder treatment market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland),  MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few. In 2017, Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug Adderall XR aimed at adolescents and adults.

The global ADHD treatment market is in budding stage, several local and international players are actively involved in the growth of the market. Launching of new products, collaborations, acquisitions and mergers, and agreements are some of the key strategies followed by various companies to increase the market share.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/

 

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl